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Abstract
Aims—Pulmonary oedema is a common and important finding in acute heart failure (AHF). We 
conducted a systematic review to describe the methods used to assess pulmonary oedema in recent 
randomized AHF trials and report its prevalence in these trials.
Methods and results—Of 23 AHF trials published between 2002 and 2013, six were excluded 
because they were very small or not randomized, or missing full-length publications. Of the 
remaining 17 (n = 200–7141) trials, six enrolled patients with HF and reduced ejection fraction 
(HF-REF) and 11, patients with both HF-REF and HF with preserved ejection fraction (HF-PEF). 
Pulmonary oedema was an essential inclusion criterion, in most trials, based upon findings on 
physical examination (‘rales’), radiographic criteria (‘signs of congestion’), or both. The 
prevalence of pulmonary oedema in HF-REF trials ranged from 75% to 83% and in combined HF-
REF and HF-PEF trials from 51% to 100%. Five trials did not report the prevalence or extent of 
pulmonary oedema assessed by either clinical examination or chest x-ray. Improvement of 
pulmonary congestion with treatment was inconsistently reported and commonly grouped with 
other signs of congestion into a score. One trial suggested that patients with rales over >2/3 of the 
lung fields on admission were at higher risk of adverse outcomes than those without.
Conclusion—Although pulmonary oedema is a common finding in AHF, represents a 
therapeutic target, and may be of prognostic importance, recent trials used inconsistent criteria to 
define it, and did not consistently report its severity at baseline or its response to treatment. 
Consistent and ideally quantitative, methods for the assessment of pulmonary oedema in AHF 
trials are needed.
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Introduction
Acute heart failure (AHF) is a leading cause of hospitalization in patients over 65 years of 
age, in both the USA and Europe, with 20–30% of patients dying within 6 months after 
discharge.1,2 Despite the improved survival seen over the past three decades with the 
advances in pharmacotherapy and device treatment of chronic heart failure with reduced 
ejection fraction (HF-REF), patients hospitalized with AHF remain at high risk of both 
inpatient and post-discharge morbidity and mortality. Therefore, identification of effective 
treatments for AHF represents an important unmet clinical need.1 Hence, the timely and 
accurate identification and characterization of patients with AHF is crucial for the successful 
conduct of clinical trials.
Currently, the diagnosis of AHF is made on the basis of a constellation of signs and 
symptoms, supported by imaging and laboratory testing.3 The presence of pulmonary 
oedema is a common sign in AHF and often used as an entry criterion in trials of therapies 
in patients with this condition.4 Clinical evidence of pulmonary oedema includes rales on 
auscultation and findings of pulmonary congestion on chest radiography.4 Newer, less 
subjective methods of assessing pulmonary oedema include impedance measurement (by 
external or implanted devices) and lung ultrasonography, although these are currently not 
routinely used in the diagnosis or monitoring of pulmonary oedema in AHF trials.5–9 Given 
that more severe pulmonary oedema is associated with a greater risk of death and re-
hospitalization, it is important to assess pulmonary oedema accurately in a reproducible 
manner.10 Quantification of pulmonary oedema is important in describing the baseline 
characteristics of patients (and the balance between treatment arms), estimating patient risk, 
and is in itself a potential endpoint in clinical trials.
We conducted a systematic review of randomized trials involving patients with AHF to 
describe the methods used to assess pulmonary oedema, how the presence and degree of 
oedema is reported, and the prevalence of pulmonary oedema in these trials.
Methods
We collected data regarding pulmonary oedema from randomized controlled clinical trials 
(RCTs) which enrolled participants with AHF.
Literature search strategy and data extraction
The electronic databases Embase (269 articles), Medline (4439 articles), and the Cochrane 
Registry of Controlled Clinical Trials (113 articles) were searched with the terms ‘heart 
failure, acute, decompensated, heart decompensation, pulmonary oedema, pulmonary 
congestion, rales, crepitations’. We excluded trials in patients with acute myocardial 
infarction. The search was limited to RCTs in humans, and studies reported in English and 
published after January 2000 were included. We excluded two studies that had only reported 
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data in abstract form (RITZ I and CASINO), three studies that had a sample size of <200 
people,11–13 and one study in which patients with suspected but not confirmed AHF were 
randomized.14 Trials meeting the inclusion criteria, study design papers, the main trial 
results paper, and supplemental files/appendices were reviewed. In addition, if secondary 
papers were published using the full data set, these were also reviewed for relevant data. We 
did not contact authors directly, but did use additional source documents from the Food and 
Drug Administration (FDA) website if available, in addition to the published information. 
Baseline characteristics and mortality rates are reported for the placebo groups if pooled 
baseline characteristics were not reported. Manuscripts were independently reviewed by two 
readers (P.S.J, and E.P.), with any discrepancies being resolved by a third reader (J.J.M.). 
The Cochrane Collaboration’s tool was used for assessing risk of bias. We found that the 
included trials had low risk for bias (Supplementary material online, Table SI). In addition, 
the PRISMA 2009 checklist was used to examine the fidelity in reporting of results 
(Supplementary material online, Table S2).
Results
We identified 17 RCTs which enrolled patients with AHF and which met our inclusion 
criteria. These were published between the years 2002 and 2013. Eleven trials enrolled 
patients irrespective of EF and six trials included only patients with HF-REF The sample 
sizes ranged from 200 to 7141 (Table 1). Trials published after 2006 were more likely to 
include natriuretic peptides as part of their inclusion criteria and were less likely to exclude 
patients with heart failure with preserved ejection fraction (HF-PEF) (Table 1).
Pulmonary congestion as an inclusion criterion
Most trials required evidence of pulmonary oedema on either physical or radiographic 
examination for inclusion (Table 1). The presence of ‘rales’ on auscultation was the most 
commonly reported requirement on physical examination. Only one trial recruiting patients 
with HF-REF (REVIVE-2), and two enrolling patients with HF-REF and HF-PEF 
(PROTECT, RELAX-AHF), assessed rales in a semi-quantitative way, reporting the 
presence of rales in thirds from the lung bases.15–17 The radiographic criteria for inclusion 
were less clearly defined and usually the requirement was described as ‘signs of congestion’ 
on the chest X-ray (CXR). One trial required findings on both physical and radiographic 
examination (3CPO) and two trials (Pre-RELAX-AHF and RELAX-AHF) required 
radiological pulmonary congestion in all patients. One study (UNLOAD) included evidence 
of pleural effusion as an indicator of pulmonary congestion.
Pulmonary congestion as the study endpoint
Pulmonary congestion alone was not used as a primary efficacy endpoint in any of the 
reviewed AHF trials, although relief of dyspnoea (presumably secondary to pulmonary 
oedema) and pulmonary oedema itself was used in conjunction with other markers of 
congestion as part of the primary endpoint in three trials and as a secondary endpoint in five 
trials (Table 2).
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Although worsening HF has recently become an outcome of interest in AHF trials, only 
three of the studies reviewed reported on whether or not worsening of pulmonary oedema 
occurred (as a safety outcome). The REVIVE-2 trial (HF-REF) reported 6% of patients with 
worsening pulmonary oedema in their placebo group, and the HF-REF and HF-PEF trials 
RITZ-2 and VERITAS reported 3% and 6% with worsening pulmonary oedema.
Pulmonary congestion at baseline
The prevalence of pulmonary oedema at baseline in trials enrolling patients with HF-REF 
ranged from 75% to 83% and in trials enrolling both patients with HF-REF and HF-PEF 
from 51% to 100%, in part depending on the inclusion criteria (Table 3). Five trials did not 
report the prevalence or degree of pulmonary oedema assessed by either physical 
examination or CXR. The EVEREST investigators found in a post-hoc analysis that subjects 
with the highest congestion score at the time of discharge/day 7 were more likely than other 
patients to have baseline jugular venous distension, and lower extremity oedema, as well as 
have the highest natriuretic peptide levels and the highest rate of prior hospitalization for 
heart failure.18 Yet these subjects had the lowest proportion of rales on auscultation at 
baseline.
Only seven trials reported the prevalence of lung disease which may cause signs similar to 
pulmonary oedema. The prevalence of COPD ranged from 9% to 30%.
Effect of therapy on pulmonary congestion
Improvement of pulmonary congestion with treatment was also inconsistently reported and 
commonly grouped with other signs of congestion, e.g. dyspnoea, heart rate, rales, and 
jugular venous pressure, into a composite ‘congestion score’ or ‘oedema score’, in which 
each sign or symptom was assigned a point value (Table 3).19,20 The treatment effect on the 
degree of congestion/oedema was then assessed longitudinally as measured by the score. For 
instance, the Heart Failure Score in a HF-REF trial, OPTIME-CHF, in which a maximum 
number of two points could be assigned to the presence of rales, with a higher score 
indicating more congestion, improved from baseline (score: 6) to hospital discharge (score: 
2) in the placebo group.21 Similarly, the SURVIVE trial reported 81% of subjects with at 
least mild improvement in a global assessment score, the VMAC trial reported that global 
clinical status ‘improved’ between 3 and 24 h, and investigators from the PROTECT trial 
reported that 36% of patients had ‘treatment success’ (defined as patient-reported 
improvement in dyspnoea at both 24 and 48 h from treatment start in the absence of 
treatment failure, including worsening HF) in the placebo group.16,22
Improvement of pulmonary congestion was reported separately in only one HF-REF 
(EVEREST) and two combined HF-REF/HF-PEF trials. The EVEREST trial reported that 
77% of patients had at least a 1 point improvement (scale 0–4) in rales on hospital day 4, the 
Pre-RELAX-AHF trial reported that 67% of subjects had no rales on day 5, and RELAX-
AHF reported that ~40% had no rales on day 2.17,23,24
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Baseline pulmonary congestion and clinical outcomes
All-cause mortality rates in the reviewed AHF trials were reported for time frames ranging 
from 28 days to 10 months and are hence difficult to compare with respect to the presence/
degree of pulmonary oedema. Where reported, all-cause mortality ranged from 3% to 16% 
(30 days) and from 11% to 38% (180 days), respectively (Table 3). In a post-hoc analysis of 
the HF-REF trial, EVEREST, a higher congestion score at the time of discharge/day 7 was 
associated with increased risk of 30-day HF hospitalization and all-cause mortality [hazard 
ratio (HR) 1.13, 95% confidence interval (CI) 1.06–1.17]. However, patients with absent or 
minimal resting signs and symptoms at discharge still experienced a high 30-day mortality 
(19%) and readmission rate (26%). Pulmonary congestion was not analysed independently 
in this report. A multivariable analysis of the HF-REF and HF-PEF trial, PROTECT, 
demonstrated that rales >2/3 from the bases (compared with no rales) on admission were 
associated with higher risk for death or hospitalization for any reason at 30 days (HR 1.49, 
95% CI 0.96–2.29), death or rehospitalization for cardiovascular or renal reasons at 30 days 
(HR 1.53, 95% CI 0.96–2.41), and all-cause mortality at 180 days (HR 1.65, 95% CI 1.07–
2.54).10 However, it was not included in their prediction model since interobserver 
variability was presumed to be high for rales on auscultation.
Discussion
In this systematic review of the assessment of pulmonary oedema in trials enrolling patients 
with AHF, we found a wide range of mainly qualitative methods of assessing and reporting 
of pulmonary oedema detected by physical or radiological examination. Although the 
majority of trials listed pulmonary oedema as one of their inclusion criteria, change of 
pulmonary oedema with treatment was rarely reported alone, and was often combined with 
other markers of congestion, such as jugular venous distension and lower limb oedema. At 
the same time, while improvement of pulmonary congestion was part of the primary or 
secondary endpoint in at least 8 of 17 of the reviewed trials, improvement of pulmonary 
oedema was not the sole endpoint in any. The lack of any quantitative assessment of 
pulmonary oedema is a concern, given that incomplete decongestion has been reported as a 
potential predictor of both HF rehospitalization and mortality25,26 Moreover, worsening HF 
as currently reported is a quite subjective outcome, and objective identification and 
quantification of pulmonary oedema would increase the robustness of this endpoint.
In 2010, the Acute Heart Failure Committee of the Heart Failure Association of the 
European Society of Cardiology (ESC) published a scientific statement on the assessment 
and grading of congestion in AHF. The authors of this document recognized that rales 
(crepitations or crackles) on auscultation are neither a sensitive nor a specific marker for 
pulmonary oedema but have the advantage of allowing rapid assessment of the patient.4 In 
addition, it was noted that a CXR was likewise not sufficiently sensitive to exclude 
pulmonary congestion.4 Similarly, the most recent ESC heart failure guidelines mention 
‘pulmonary crepitations’ as a less specific sign in the diagnosis of HF. They also suggest 
that CXR may be of limited use in the diagnostic evaluation of patients with suspected HF 
but can be useful to identify alternative diagnoses and may show findings consistent with 
pulmonary oedema/congestion.3
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In trials of patients with AHF with similar age, LVEF, baseline renal function, and systolic 
blood pressure, the prevalence of pulmonary oedema ranged from 54% in ROSE to 90% in 
PROTECT. While this wide variation could be due to other differences in the patients 
enrolled, it is perhaps more likely to be due to inconsistent definition of pulmonary oedema, 
either on physical or on radiological examination, or due to interobserver variability related 
to both methods. While independent imaging core laboratory review of echocardiographic 
studies is commonly performed in HF trials, similar evaluation of CXR findings is not 
undertaken. Standardized criteria for both auscultation and analysis of imaging studies may 
help reduce this variability and allow for better monitoring of pulmonary oedema with 
treatment, as well as assessment of residual pre-discharge congestion.
Although the composite reporting of signs of congestion as a ‘congestion score’ may be 
useful as a primary or secondary study endpoint, reporting of individual congestion 
components may be equally important to gain a better understanding of the treatment effect 
of new therapies on each of these components. It is conceivable that pulmonary oedema, 
when measured consistently and with sensitive and specific methods, may be present at 
baseline and change to variable degrees with treatment in different AHF phenotypes, 
depending on the chronicity and aetiology of AHF, as well as the associated 
pathophysiological and anatomical pulmonary changes. In a time-to-first event analysis in 
the RELAX-AHF trial, the effect size for the treatment comparisons in physician-assessed 
HF signs and symptoms through day 5 ranged from 19% (rales) to 33% (peripheral oedema) 
relative improvement in serelaxin compared with placebo patients, but did not significantly 
change estimated jugular venous pressure.27
Quantitative imaging markers of pulmonary oedema, such as lung ultrasonography, would 
make such standardization more feasible. The reported sensitivity of lung ultrasound is 94% 
(95% CI 81–98%) with a specificity of 92% (95% CI 84–96%) for the identification of a 
cardiogenic aetiology in patients presenting to emergency departments with undifferentiated 
dyspnoea.28,29 When interpreted by clinicians at the point of care, lung ultrasound had a 
significantly higher accuracy (sensitivity 97%, 95% CI 95–98%; specificity 97%, 95% CI 
96–99%) in differentiating AHF from non-cardiac causes of acute dyspnoea than the initial 
clinical work-up or CXR alone in a recent European multicentre study in >1000 dyspnoeic 
patients.29 Interobserver agreement for lung ultrasound findings in pulmonary oedema is 
high,28,30,31 and this technique is a potentially useful method of accurately identifying 
patients with HF and monitoring pulmonary congestion in trials of patients with AHF, 
although these findings need to be confirmed in larger studies.9,32–34 In addition, external 
and implanted impedance measurement devices have been proposed as potential future tools 
in the assessment of pulmonary congestion.4 These devices have been investigated as 
assessment and monitoring devices for pulmonary oedema, although with inconsistent 
findings with respect to their diagnostic and prognostic utility in HF populations.35–37
Data from one of the reviewed AHF trials in both HF-REF and HF-PEF patients suggest that 
rales on auscultation at the time of admission may provide additional prognostic 
information.10 Composite congestion scores make the identification of individual signs and 
symptoms of congestion with respect to prognostic importance more difficult. Similar to 
other outcome measures, reporting of individual congestion components may allow for a 
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better understanding not only of the effects of therapy but also of their relationship to 
outcomes. Whether baseline or pre-discharge pulmonary congestion is as important as other 
signs of congestion (e.g. peripheral oedema) is equally unclear without consistent 
assessment and reporting in AHF trials.
Recommendation for assessment of pulmonary congestion in future acute heart failure 
trials
Based on the heterogeneity of definitions and criteria, we recommend a standardized 
approach for the assessment and reporting of pulmonary oedema in future AHF trials. We 
suggest the following definitions for pulmonary oedema (Table 4, Figures 1 and 2).
Clinical examination—Presence of crackles or rales on auscultation should be assessed in 
thirds from the lung bases:10
• No crackles/rales
• Crackles/rales ≤1/3 from bases
• Crackles/rales ≤2/3 from bases
• Crackles/rales >2/3 from bases
Lung ultrasound—B-mode lung ultrasound assessment of the anterior and lateral chest 
can be performed with a variety of ultrasound machines routinely used in clinical practice. A 
curvilinear or phased array transducer in 6– 8 intercostal spaces [3 (or 4) on each 
hemithorax] can be used to assess for the presence of B-lines (vertical lines arising from the 
pleural line) at an imaging depth of ~18 cm, although imaging of four intercostal spaces 
(zones) may be sufficient in AHF (Figure 2).29,38–40 The presence of ≥3 B-lines per zone in 
at least two zones on each hemithorax should be considered diagnostic for pulmonary 
oedema in suspected AHF.28,29,38 Both patient positioning (upright vs. supine) and duration 
of recorded clips should be kept constant if serial assessments are performed.39,40 A 
decrease in B-line number can be observed with treatment of AHF.9 Potential false-positive 
results can be seen in a variety of interstitial lung processes, such as pulmonary fibrosis, so it 
is important to interpret the findings in the clinical context and taking account of the results 
of other investigations, e.g. natriuretic peptides.38 The presence of pleural effusions can be 
assessed at the diaphragmatic level laterally on each hemithorax (Figure 2).41,42
Chest radiography—Chest radiography may be useful in identifying alternative 
aetiologies of dyspnoea. In settings where ultrasound is not available, CXR can be used to 
identify pulmonary congestion, however, with lower sensitivity than lung ultrasound (Table 
4).
Limitations
This systematic review should be considered in the context of its limitations. Given the 
heterogeneity in the assessment methods and reporting of pulmonary congestion in the 
reviewed AHF trials, we could not perform a meta-analysis of the reviewed data. Although 
all reviewed studies were randomized trials in AHF cohorts, differences with respect to 
Platz et al. Page 7
Eur J Heart Fail. Author manuscript; available in PMC 2016 September 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
inclusion criteria and time to intervention make it difficult to compare the response to 
therapeutic interventions.
Conclusions
Although pulmonary oedema is a common sign in patients with AHF, and may be of 
prognostic importance, recent trials have used variable diagnostic criteria, and have not 
consistently reported either baseline severity or response to treatment. When reported, the 
prevalence of pulmonary oedema has varied greatly. Consistent, ideally quantitative, 
methods for the assessment of pulmonary oedema in AHF are needed.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
Funding
This work was in part supported by grants from the National Heart, Lung, and Blood Institute at the National 
Institutes of Health [grant no. 1K23HL123533-01A1 to E.P] and the British Heart Foundation [grant no. PG/
13/17/30050 to R.T.C. and J.J.M.). The sponsors had no input or contribution in the development of the research 
and manuscript.
References
1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, Dai S, Ford ES, Fox CS, 
Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Judd SE, 
Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Mackey RH, Magid DJ, Marcus 
GM, Marelli A, Matchar DB, McGuire DK, Mohler ER 3rd, Moy CS, Mussolino ME, Neumar RW, 
Nichol G, Pandey DK, Paynter NP, Reeves MJ, Sorlie PD, Stein J, Towflghi A, Turan TN, Virani 
SS, Wong ND, Woo D, Turner MB. Heart disease and stroke statistics—2014 update: a report from 
the American Heart Association. Circulation. 2013; 129:e28–e292. [PubMed: 24352519] 
2. Jhund PS, Macintyre K, Simpson CR, Lewsey JD, Stewart S, Redpath A, Chalmers JW, Capewell S, 
McMurray JJ. Long-term trends in first hospitalization for heart failure and subsequent survival 
between 1986 and 2003: a population study of 5.1 million people. Circulation. 2009; 119:515–523. 
[PubMed: 19153268] 
3. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos 
G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, 
Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade 
PT, Voors AA, Zannad F, Zeiher A, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard 
R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, 
Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, Bonet LA, 
Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf 
FA, Guida GF, Hardman S, lung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis 
JT, Ponikowski P. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 
2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of 
the European Society of Cardiology. Developed in collaboration with the Heart Failure Association 
(HFA) of the ESC. Eur J Heart Fail. 2012; 14:803–869. [PubMed: 22828712] 
4. Gheorghiade M, Follath F, Ponikowski P, Barsuk JH, Blair JE, Cleland JG, Dickstein K, Drazner 
MH, Fonarow GC, Jaarsma T, Jondeau G, Sendon JL, Mebazaa A, Metra M, Nieminen M, Pang PS, 
Seferovic P, Stevenson LW, van Veldhuisen DJ, Zannad F, Anker SD, Rhodes A, McMurray JJ, 
Filippatos G. Assessing and grading congestion in acute heart failure: a scientific statement from the 
acute heart failure committee of the heart failure association of the European Society of Cardiology 
Platz et al. Page 8
Eur J Heart Fail. Author manuscript; available in PMC 2016 September 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
and endorsed by the European Society of Intensive Care Medicine. Eur J Heart Fail. 2010; 12:423–
433. [PubMed: 20354029] 
5. Yu CM, Wang L, Chau E, Chan RH, Kong SL, Tang MO, Christensen J, Stadler RW, Lau CP. 
Intrathoracic impedance monitoring in patients with heart failure: correlation with fluid status and 
feasibility of early warning preceding hospitalization. Circulation. 2005; 112:841–848. [PubMed: 
16061743] 
6. Packer M, Abraham WT, Mehra MR, Yancy CW, Lawless CE, Mitchell JE, Smart FW, Bijou R, 
O’Connor CM, Massie BM, Pina IL, Greenberg BH, Young JB, Fishbein DP, Hauptman PJ, Bourge 
RC, Strobeck JE, Murali S, Schocken D, Teerlink JR, Levy WC, Trupp RJ, Silver MA. Utility of 
impedance cardiography for the identification of short-term risk of clinical decompensation in stable 
patients with chronic heart failure. J Am Coll Cardiol. 2006; 47:2245–2252. [PubMed: 16750691] 
7. Platz E, Hempel D, Pivetta E, Rivero J, Solomon SD. Echocardiography and lung ultrasound 
characteristics in ambulatory patients with dyspnea or prior heart failure. Echocardiography. 2014; 
31:133–139. [PubMed: 24028294] 
8. Gargani L, Frassi F, Soldati G, Tesorio P, Gheorghiade M, Picano E. Ultrasound lung comets for the 
differential diagnosis of acute cardiogenic dyspnoea: a comparison with natriuretic peptides. Eur J 
Heart Fail. 2008; 10:70–77. [PubMed: 18077210] 
9. Volpicelli G, Caramello V, Cardinale L, Mussa A, Bar F, Frascisco MF. Bedside ultrasound of the 
lung for the monitoring of acute decompensated heart failure. Am J Emerg Med. 2008; 26:585–591. 
[PubMed: 18534289] 
10. Cleland JG, Chiswell K, Teerlink JR, Stevens S, Fiuzat M, Givertz MM, Davison BA, Mansoor 
GA, Ponikowski P, Voors AA, Cotter G, Metra M, Massie BM, O’Connor CM. Predictors of 
postdischarge outcomes from information acquired shortly after admission for acute heart failure: 
a report from the Placebo-Controlled Randomized Study of the Selective A1 Adenosine Receptor 
Antagonist Rolo-fylline for Patients Hospitalized With Acute Decompensated Heart Failure and 
Volume Overload to Assess Treatment Effect on Congestion and Renal Function (PROTECT) 
Study. Circ Heart Fail. 2014; 7:76–87. [PubMed: 24281134] 
11. Shah SJ, Blair JE, Filippatos GS, Macarie C, Ruzyllo W, Korewicki J, Bubenek-Turconi SI, 
Ceracchi M, Bianchetti M, Carminati P, Kremastinos D, Grzybowski J, Valentini G, Sabbah HN, 
Gheorghiade M. Effects of istarox-ime on diastolic stiffness in acute heart failure syndromes: 
results from the Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a 
Novel Intravenous Inotropic and Lusitropic Agent: a Randomized Controlled Trial in Patients 
Hospitalized with Heart Failure (HORIZON-HF) trial. Am Heart J. 2009; 157:1035–1041. 
[PubMed: 19464414] 
12. Bart BA, Goldsmith SR, Lee KL, Givertz MM, O’Connor CM, Bull DA, Redfield MM, Deswal A, 
Rouleau JL, LeWinter MM, Ofili EO, Stevenson LW, Semigran MJ, Felker GM, Chen HH, 
Hernandez AF, Anstrom KJ, McNulty SE, Velazquez EJ, Ibarra JC, Mascette AM, Braunwald E. 
Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med. 2012; 
367:2296–2304. [PubMed: 23131078] 
13. Aliti GB, Rabelo ER, Clausell N, Rohde LE, Biolo A, Beck-da-Silva L. Aggressive fluid and 
sodium restriction in acute decompensated heart failure: a randomized clinical trial. JAMA Intern 
Med. 2013; 173:1058–1064. [PubMed: 23689381] 
14. Maisel A, Mueller C, Nowak R, Peacock WF, Landsberg JW, Ponikowski P, Mockel M, Hogan C, 
Wu AH, Richards M, Clopton P, Filippatos GS, Di Somma S, Anand I, Ng L, Daniels LB, Neath 
SX, Christenson R, Potocki M, McCord J, Terracciano G, Kremastinos D, Hartmann O, von 
Haehling S, Bergmann A, Morgenthaler NG, Anker SD. Mid-region pro-hormone markers for 
diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart 
Failure) trial. J Am Coll Cardiol. 2010; 55:2062–2076. [PubMed: 20447528] 
15. Packer M, Colucci W, Fisher L, Massie BM, Teerlink JR, Young J, Padley RJ, Thakkar R, 
Delgado-Herrera L, Salon J, Garratt C, Huang B, Sarapohja T. Effect of levosimendan on the 
short-term clinical course of patients with acutely decompensated heart failure. JACC Heart Fail. 
2013; 1:103–111. [PubMed: 24621834] 
16. Massie BM, O’Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, Weatherley BD, 
Cleland JG, Givertz MM, Voors A, DeLucca P, Mansoor GA, Salerno CM, Bloomfield DM, 
Platz et al. Page 9
Eur J Heart Fail. Author manuscript; available in PMC 2016 September 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Dittrich HC. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J 
Med. 2010; 363:1419–1428. [PubMed: 20925544] 
17. Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Ponikowski P, 
Unemori E, Voors AA, Adams KF Jr, Dorobantu Ml, Grinfeld LR, Jondeau G, Marmor A, Masip 
J, Pang PS, Werdan K, Teichman SL, Trapani A, Bush CA, Saini R, Schumacher C, Severin TM, 
Metra M. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-
AHF): a randomised, placebo-controlled trial. Lancet. 2013; 381:29–39. [PubMed: 23141816] 
18. Ambrosy AP, Pang PS, Khan S, Konstam MA, Fonarow GC, Traver B, Maggioni AP, Cook T, 
Swedberg K, Burnett JC Jr, Grinfeld L, Udelson JE, Zannad F, Gheorghiade M. Clinical course 
and predictive value of congestion during hospitalization in patients admitted for worsening signs 
and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial. 
Eur Heart J. 2013; 34:835–843. [PubMed: 23293303] 
19. Cuffe MS, Califf RM, Adams KF, Bourge RC, Colucci W, Massie B, O’Connor CM, Pina I, Quigg 
R, Silver M, Robinson LA, Leimberger JD, Gheorghiade M. Rationale and design of the OPTIME 
CHF trial: outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic 
heart failure. Am Heart J. 2000; 139:15–22. [PubMed: 10618557] 
20. Gheorghiade M, Orlandi C, Burnett JC, Demets D, Grinfeld L, Maggioni A, Swedberg K, Udelson 
JE, Zannad F, Zimmer C, Konstam MA. Rationale and design of the multicenter, randomized, 
double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in 
Heart Failure: Outcome Study with Tolvaptan (EVEREST). J Card Fail. 2005; 11:260–269. 
[PubMed: 15880334] 
21. Cuffe MS, Califf RM, Adams KF Jr, Benza R, Bourge R, Colucci WS, Massie BM, O’Connor CM, 
Pina I, Quigg R, Silver MA, Gheorghiade M. Short-term intravenous milrinone for acute 
exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002; 287:1541–1547. 
[PubMed: 11911756] 
22. Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, Thakkar R, Padley 
RJ, Poder P, Kivikko M. Levosimendan vs dobutamine for patients with acute decompensated 
heart failure: the SURVIVE Randomized Trial. JAMA. 2007; 297:1883–1891. [PubMed: 
17473298] 
23. Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, 
Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C. Effects of oral tolvaptan in patients 
hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007; 297:1319–
1331. [PubMed: 17384437] 
24. Teerlink JR, Metra M, Felker GM, Ponikowski P, Voors AA, Weatherley BD, Marmor A, Katz A, 
Grzybowski J, Unemori E, Teichman SL, Cotter G. Relaxin for the treatment of patients with 
acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-
group, dose-finding phase lib study. Lancet. 2009; 373:1429–1439. [PubMed: 19329178] 
25. Lucas C, Johnson W, Hamilton MA, Fonarow GC, Woo MA, Flavell CM, Creaser JA, Stevenson 
LW. Freedom from congestion predicts good survival despite previous class IV symptoms of heart 
failure. Am Heart J. 2000; 140:840–847. [PubMed: 11099986] 
26. Kociol RD, McNulty SE, Hernandez AF, Lee KL, Redfield MM, Tracy RP, Braunwald E, 
O’Connor CM, Felker GM. Markers of decongestion, dyspnea relief, and clinical outcomes among 
patients hospitalized with acute heart failure. Circ Heart Fail. 2013; 6:240–245. [PubMed: 
23250981] 
27. Novartis. Reasanz™ (Serelaxin): Briefing document. 2015 Mar 4. http://www.fda.gov/downloads/
AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/
CardiovascularandRenalDrugsAdvisoryCommittee/UCM390444.pdf
28. Al Deeb M, Barbic S, Featherstone R, Dankoff J, Barbic D. Point-of-care ultrasonography for the 
diagnosis of acute cardiogenic pulmonary edema in patients presenting with acute dyspnea: a 
systematic review and meta-analysis. Acad Emerg Med. 2014; 21:843–852. [PubMed: 25176151] 
29. Pivetta E, Goffi A, Lupia E, Tizzani M, Porrino G, Ferreri E, Volpicelli G, Balzaretti P, Banderali 
A, lacobucci A, Locatelli S, Casoli G, Stone MB, Maule MM, Baldi I, Merletti F, Cibinel G. Lung 
ultrasound-implemented diagnosis of acute decompensated heart failure in the Emergency 
Department—a SIMEU multicenter study. Chest. 2015; 148(1):202–210. [PubMed: 25654562] 
Platz et al. Page 10
Eur J Heart Fail. Author manuscript; available in PMC 2016 September 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
30. Platz E, Lattanzi A, Agbo C, Takeuchi M, Resnic FS, Solomon SD, Desai AS. Utility of lung 
ultrasound in predicting pulmonary and cardiac pressures. Eur J Heart Fail. 2012; 14:1276–1284. 
[PubMed: 22962280] 
31. Bedetti G, Gargani L, Corbisiero A, Frassi F, Poggianti E, Mottola G. Evaluation of ultrasound 
lung comets by hand-held echocardiography. Cardiovasc Ultrasound. 2006; 4:34. [PubMed: 
16945139] 
32. Noble VE, Murray AF, Capp R, Sylvia-Reardon MH, Steele DJ, Liteplo A. Ultrasound assessment 
for extravascular lung water in patients undergoing hemodialysis. Time course for resolution. 
Chest. 2009; 135:1433–1439. [PubMed: 19188552] 
33. Trezzi MTorzillo D, Ceriani E, Costantino G, Caruso S, Damavandi PT, Genderini A, Cicardi M, 
Montano N, Cogliati C. Lung ultrasonography for the assessment of rapid extravascular water 
variation: evidence from hemodialysis patients. Intern Emerg Med. 2011; 8:409–415. [PubMed: 
21590437] 
34. Fagenholz PJ, Gutman JA, Murray AF, Noble VE, Thomas SH, Harris NS. Chest ultrasonography 
for the diagnosis and monitoring of high-altitude pulmonary edema. Chest. 2007; 131:1013–1018. 
[PubMed: 17426204] 
35. Conraads VM, Tavazzi L, Santini M, Oliva F, Gerritse B, Yu CM, Cowie MR. Sensitivity and 
positive predictive value of implantable intrathoracic impedance monitoring as a predictor of heart 
failure hospitalizations: the SENSE-HF trial. Eur Heart J. 2011; 32:2266–2273. [PubMed: 
21362703] 
36. Di Somma S, Lalle I, Magrini L, Russo V, Navarin S, Castello L, Avanzi GC, Di Stasio E, Maisel 
A. Additive diagnostic and prognostic value of bioelectrical impedance vector analysis (BIVA) to 
brain natriuretic peptide ‘grey-zone’ in patients with acute heart failure in the emergency 
department. Eur Heart J Acute Cardiovasc Care. 2014; 3:167–175. [PubMed: 24477201] 
37. Heist EK, Herre JM, Binkley PF, Van Bakel AB, Porterfield JG, Porterfield LM, Qu F, Turkel M, 
Pavri BB. Analysis of different device-based intrathoracic impedance vectors for detection of heart 
failure events (from the Detect Fluid Early from Intrathoracic Impedance Monitoring Study). Am J 
Cardiol. 2014; 114:1249–1256. [PubMed: 25150135] 
38. Volpicelli G, Elbarbary M, Blaivas M, Lichtenstein DA, Mathis G, Kirkpatrick AW, Melniker L, 
Gargani L, Noble VE, Via G, Dean A, Tsung JW, Soldati G, Copetti R, Bouhemad B, Reissig A, 
Agricola E, Rouby JJ, Arbelot C, Liteplo A, Sargsyan A, Silva F, Hop.p.m.ann R, Breitkreutz R, 
Seibel A, Neri L, Storti E, Petrovic T. International evidence-based recommendations for point-of-
care lung ultrasound. Intensive Care Med. 2012; 38:577–591. [PubMed: 22392031] 
39. Frasure SE, Matilsky DK, Siadecki SD, Platz E, Saul T, Lewiss RE. Impact of patient positioning 
on lung ultrasound findings in acute heart failure. Eur Heart J Acute Cardiovasc Care. 2015 pii: 
2048872614551505 [Epub ahead of print]. 
40. Platz E, Pivetta E, Merz A, Peck J, Rivero J, Cheng S. Impact of device selection and clip duration 
on lung ultrasound assessment in patients with heart failure. Am J Emerg Med. 2015 pii: 
S0735-6757(15)00466-0. [Epub ahead of print]. 
41. Cibinel GA, Casoli G, Elia F, Padoan M, Pivetta E, Lupia E, Goffi A. Diagnostic accuracy and 
reproducibility of pleural and lung ultrasound in discriminating cardiogenic causes of acute 
dyspnea in the emergency department. Intern Emerg Med. 2011; 7:65–70. [PubMed: 22033792] 
42. Russell FM, Ehrman RR, Cosby K, Ansari A, Tseeng S, Christain E, Bailitz J. Diagnosing acute 
heart failure in patients with undifferentiated dyspnea: a lung and cardiac ultrasound (LuCUS) 
protocol. Acad Emerg Med. 2015; 22:182–191. [PubMed: 25641227] 
43. Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, Harjola VP, Mitrovic V, 
Abdalla M, Sandell EP, Lehtonen L. Efficacy and safety of intravenous levosimendan compared 
with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind 
trial. Lancet. 2002; 360:196–202. [PubMed: 12133653] 
44. Gheorghiade M, Gattis WA, Barbagelata A, Adams KF Jr, Elkayam U, Orlandi C, O’Connor CM. 
Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study 
of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with 
worsening congestive heart failure. Am Heart J. 2003; 145(2 Suppl):S51–S54. [PubMed: 
12594452] 
Platz et al. Page 11
Eur J Heart Fail. Author manuscript; available in PMC 2016 September 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
45. Gheorghiade M, Gattis WA, O’Connor CM, Adams KF Jr, Elkayam U, Barbagelata A, Ghali JK, 
Benza RL, McGrew FA, Klapholz M, Ouyang J, Orlandi C. Effects of tolvaptan, a vasopressin 
antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. 
JAMA. 2004; 291:1963–1971. [PubMed: 15113814] 
46. Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, 
Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C. Short-term clinical effects of tolvaptan, an 
oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status 
Trials. JAMA. 2007; 297:1332–1343. [PubMed: 17384438] 
47. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute 
CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart 
failure: a randomized controlled trial. JAMA. 2002; 287:1531–1540. [PubMed: 11911755] 
48. Torre-Amione G, Young JB, Colucci WS, Lewis BS, Pratt C, Cotter G, Stangl K, Elkayam U, 
Teerlink JR, Frey A, Rainisio M, Kobrin I. Hemodynamic and clinical effects of tezosentan, an 
intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated 
heart failure. J Am Coll Cardiol. 2003; 42:140–147. [PubMed: 12849674] 
49. Costanzo MR, Guglin ME, Saltzberg MT, Jessup ML, Bart BA, Teerlink JR, Jaski BE, Fang JC, 
Feller ED, Haas GJ, Anderson AS, Schollmeyer MP, Sobotka PA. Ultrafiltration versus 
intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll 
Cardiol. 2007; 49:675–683. [PubMed: 17291932] 
50. Teerlink JR, McMurray JJ, Bourge RC, Cleland JG, Cotter G, Jondeau G, Krum H, Metra M, 
O’Connor CM, Parker JD, Torre-Amione G, Van Veldhuisen DJ, Frey A, Rainisio M, Kobrin I. 
Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor 
Inhibition with Tezosentan in Acute heart failure Study (VERITAS). Am Heart J. 2005; 150:46–
53. [PubMed: 16084150] 
51. McMurray JJ, Teerlink JR, Cotter G, Bourge RC, Cleland JG, Jondeau G, Krum H, Metra M, 
O’Connor CM, Parker JD, Torre-Amione G, van Veldhuisen DJ, Lewsey J, Frey A, Rainisio M, 
Kobrin I. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart 
failure: the VERITAS randomized controlled trials. JAMA. 2007; 298:2009–2019. [PubMed: 
17986694] 
52. Gray A, Goodacre S, Newby DE, Masson M, Sampson F, Nicholl J. Noninvasive ventilation in 
acute cardiogenic pulmonary edema. N Engl J Med. 2008; 359:142–151. [PubMed: 18614781] 
53. Gray AJ, Goodacre S, Newby DE, Masson MA, Sampson F, Dixon S, Crane S, Elliott M, Nicholl 
J. A multicentre randomised controlled trial of the use of continuous positive airway pressure and 
non-invasive positive pressure ventilation in the early treatment of patients presenting to the 
emergency department with severe acute cardiogenic pulmonary oedema: the 3CPO trial. Health 
Technol Assess. 2009; 13:1–106.
54. Weatherley BD, Cotter G, Dittrich HC, DeLucca P, Mansoor GA, Bloom-field DM, Ponikowski P, 
O’Connor CM, Metra M, Massie BM. Design and rationale of the PROTECT study: a placebo-
controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for 
patients hospitalized with acute decompensated heart failure and volume overload to assess 
treatment effect on congestion and renal function. J Card Fail. 2010; 16:25–35. [PubMed: 
20123315] 
55. Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, LeWinter MM, 
Deswal A, Rouleau JL, Ofili EO, Anstrom KJ, Hernandez AF, McNulty SE, Velazquez EJ, Kfoury 
AG, Chen HH, Givertz MM, Semigran MJ, Bart BA, Mascette AM, Braunwald E, O’Connor CM. 
Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011; 
364:797–805. [PubMed: 21366472] 
56. Hernandez AF, O’Connor CM, Starling RC, Reist CJ, Armstrong PW, Dickstein K, Lorenz TJ, 
Gibler WB, Hasselblad V, Komajda M, Massie B, McMurray JJ, Nieminen M, Rouleau JL, 
Swedberg K, Califf RM. Rationale and design of the Acute Study of Clinical Effectiveness of 
Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). Am Heart J. 2009; 157:271–277. 
[PubMed: 19185633] 
57. O’Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, Heizer 
GM, Komajda M, Massie BM, McMurray JJ, Nieminen MS, Reist CJ, Rouleau JL, Swedberg K, 
Adams KF Jr, Anker SD, Atar D, Battler A, Botero R, Bohidar NR, Butler J, Clausell N, Corbalan 
Platz et al. Page 12
Eur J Heart Fail. Author manuscript; available in PMC 2016 September 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
R, Costanzo MR, Dahlstrom U, Deck-elbaum LI, Diaz R, Dunlap ME, Ezekowitz JA, Feldman D, 
Felker GM, Fonarow GC, Gennevois D, Gottlieb SS, Hill JA, Hollander JE, Howlett JG, Hudson 
MP, Kociol RD, Krum H, Laucevicius A, Levy WC, Mendez GF, Metra M, Mittal S, Oh BH, 
Pereira NL, Ponikowski P, Tang WH, Tanomsup S, TeerlinkJR Triposkiadis F, Troughton RW, 
Voors AA, Whellan DJ, Zannad F, Califf RM. Effect of nesiritide in patients with acute 
decompensated heart failure. N Engl J Med. 2011; 365:32–43. [PubMed: 21732835] 
58. Chen HH, Anstrom KJ, Givertz MM, Stevenson LW, Semigran MJ, Goldsmith SR, Bart BA, Bull 
DA, Stehlik J, LeWinter MM, Konstam MA, Huggins GS, Rouleau JL, O’Meara E, Tang WH, 
Starling RC, Butler J, Deswal A, Felker GM, O’Connor CM, Bonita RE, Margulies KB, Cappola 
TP, Ofili EO, Mann DL, Davila-Roman VG, McNulty SE, Borlaug BA, Velazquez EJ, Lee KL, 
Shah MR, Hernandez AF, Braunwald E, Redfield MM. Low-dose dopamine or low-dose nesiritide 
in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. 
JAMA. 2013; 310:2533–2543. [PubMed: 24247300] 
59. Wang CS, FitzGerald JM, Schulzer M, Mak E, Ayas NT. Does this dyspneic patient in the 
emergency department have congestive heart failure? JAMA. 2005; 294:1944–1956. [PubMed: 
16234501] 
Platz et al. Page 13
Eur J Heart Fail. Author manuscript; available in PMC 2016 September 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 1. 
Diagnostic flowchart for pulmonary congestion assessment in acute heart failure (AHF) 
trials. *Depending on the availability of imaging modalities and operator experience, lung 
ultrasound or chest radiography can be used in the assessment of pulmonary congestion. 
However, lung ultrasound will identify pulmonary oedema with higher sensitivity and 
specificity than chest radiography. Both imaging techniques may be useful in identifying 
alternative aetiologies of dyspnoea (e.g. pneumonia, pneumothorax, lung mass).
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Figure 2. 
Lung and pleural ultrasound. (A) Lung ultrasound: probe positioning for image acquisition. 
(B) Pleural ultrasound: the star indicates pleural effusion. (C) Lung ultrasound: normal 
appearance without B-lines. (D) Lung ultrasound: multiple B-lines; arrows indicate vertical 
B-lines.
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Table 4
Recommendations for assessment of pulmonary congestion in acute heart failure trials
Diagnostic modality Findings Sensitivity (%) Specificity (%) Comments
Physical examination59 Crackles/rales 60 78 Crackles/rales >2/3 from lung bases
associated with increased risk of CV
events and mortality10
Lung ultrasound28,29 ≥3 B-lines in ≥2 intercostal
spaces bilaterally
94 (95% CI
81–98)
92 (95% CI
84–96)
False-positive examinations include acute
and chronic conditions with interstitial
involvement, such as pulmonary fibrosis38
Pleural ultrasound41,42 Pleural effusion(s) (any EF) 84 83
Pleural effusion(s) (if EF
<45%)
79 (95% CI
63–89%)
98 (95% CI
92–99)
Chest radiography59 Pulmonary vascular/venous
congestion
54 96
Any oedema 70 77
Pleural effusion(s) 26 92
CI, confidence interval; CV, cardiovascular.
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